AACR 2009: Frequent JAK Mutations in Pediatric Acute Lymphoblastic Leukemia (ALL) with Poor Outcome: A New Therapeutic Target in Resistant Disease

Bookmark and Share
Published: 30 Apr 2009
Views: 14687
Rating:
Save
Dr Charles Mullighan - Department of Pathology, St Jude Children's Research Hospital
Charles Mullighan, M.B.B.S. (Hons), M.Sc., M.D., assistant member, department of pathology, St. Jude Children’s Research Hospital presents at the 2009 AACR conference in Denver: Frequent JAK Mutations in Pediatric Acute Lymphoblastic Leukemia (ALL) with Poor Outcome: A New Therapeutic Target in Resistant Disease